A Phase 3 switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe Disease

Trial ID or NCT#

NCT01924845

Status

not recruiting iconNOT RECRUITING

Purpose

To study the safety and efficacy of the study medication, BMN 701 in patients with late onset Pompe Disease.

Investigator(s)

John W. Day, MD, PhD

View on ClinicalTrials.gov